SOURCE: Daxor Corp.

February 28, 2007 08:30 ET

Daxor Announces Emory University Hospital of Atlanta, GA Acquires BVA-100 Blood Volume Analyzer

NEW YORK, NY -- (MARKET WIRE) -- February 28, 2007 -- Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Emory University Hospital of Atlanta, Georgia.

Emory University Hospital is a 587-bed facility specializing in the care of the acutely ill adult. The hospital is located on the Emory University campus in northeast Atlanta. More than 22,999 inpatients and some 81,364 outpatients come to Emory University Hospital each year. Patients receive care from physicians of the Emory Clinic, who also are faculty of the Emory University School of Medicine, and from a highly trained staff of nurses and other clinical professionals.

Emory University Hospital provides a full range of specialized care and is recognized as one of the nation's leaders in cardiology and cardiac surgery, neurology, oncology, orthopaedics and transplantation. Emory University Hospital has been included in U.S. News and World Report's "America's Best Hospitals" for several years as one of the nation's top 10 cardiology centers.

Daxor's Blood Volume Analyzer BVA-100 will be located within Emory University Hospital's Nuclear Medicine Department, and will be utilized to diagnose patient blood volume derangements in hematology, cardiology and within various critical care units.

Other nationally renowned hospitals which have purchased the BVA-100 Blood Volume Analyzer after using it on a clinical trial basis are The Mayo Clinic, The Cleveland Clinic, and New Your University Medical Center. Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.

Contact Information

  • Contact Information:

    Stephen Feldschuh
    Chief Operating Officer
    212-330-8515
    Email Contact

    Diane Meegan
    Investor Relations
    212-330-8512
    Email Contact